13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001795097
Total reported value
$544.2M
$544.2M
55 檔
52.9%
As reported in its official Q2 2025 Form 13F filing, Privium Fund Management B.V.'s tracked investment portfolio stood at $544.2M with 55 total positions.
During Q2 2025, Privium Fund Management B.V.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPOT | Spotify Technology S.A. | Stock-Comm Services | 18.30% | -2.12% | -21.38% | |
| 2 | TSLA | Tesla Inc | Stock-Consumer Disc | 16.11% | +0.44% | +10.00% | |
| 3 | SHOP | Shopify Inc - Class A | Stock-Tech | 10.57% | -2.29% | +3.61% | |
| 4 | PLTR | Palantir Technologies Inc-a | Stock-Tech | 10.05% | -1.80% | -2.78% | |
| 5 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 7.07% | +0.71% | +5.67% | |
| 6 | SE | Sea Ltd-adr | Stock-Comm Services | 7.01% | -2.38% | EXIT | |
| 7 | COIN | Coinbase Global Inc -class A | Stock-Financials | 5.22% | -2.87% | EXIT | |
| 8 | NVDA | Nvidia CORP | Stock-Tech | 2.70% | +0.04% | +10.96% | |
| 9 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.31% | +0.13% | — | |
| 10 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 2.17% | +0.05% | +0.24% | |
| 11 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.13% | -1.28% | -2.70% | |
| 12 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.98% | +0.49% | +1.40% | |
| 13 | QURE | uniQure N.V. | Stock-Other | 1.35% | +1.12% | -22.73% | |
| 14 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.17% | -0.27% | — | |
| 15 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.04% | — | +43.80% | |
| 16 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.02% | +0.35% | +5.76% | |
| 17 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.00% | -0.09% | — | |
| 18 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.81% | -0.20% | — | |
| 19 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.68% | — | — | |
| 20 | MRNA | Moderna Inc | Stock-Healthcare | 0.64% | +0.07% | +36.86% | |
| 21 | BIIB | Biogen Inc | Stock-Healthcare | 0.58% | +0.25% | — | |
| 22 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.47% | +0.03% | -25.62% | |
| 23 | ABEV | Ambev Sa-adr | Stock-Consumer Staples | 0.42% | -0.12% | -1.05% | |
| 24 | CVNA | Carvana Co | Stock-Consumer Disc | 0.36% | — | — | |
| 25 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.30% | +0.53% | — | |
| 26 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.30% | — | — | |
| 27 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.28% | — | +33.33% | |
| 28 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.28% | +0.16% | +24.10% | |
| 29 | BNTX | Biontech Se-adr | Stock-Other | 0.25% | +0.01% | — | |
| 30 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.24% | -0.03% | — | |
| 31 | HIMS | Hims & Hers Health Inc | Stock-Healthcare | 0.24% | +0.34% | — | |
| 32 | MGTX | MeiraGTx Holdings plc | Stock-Other | 0.23% | +0.11% | +39.32% | |
| 33 | PFE | Pfizer Inc | Stock-Healthcare | 0.20% | -0.31% | EXIT | |
| 34 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.19% | -0.10% | +19.37% | |
| 35 | PAAS | Pan American Silver CORP | Stock-Materials | 0.18% | -0.04% | EXIT | |
| 36 | NOV | Nov Inc | Stock-Energy | 0.18% | -0.02% | +28.41% | |
| 37 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.18% | -0.11% | +50.73% | |
| 38 | URNM | Sprott Uranium Miners ETF | ETF-Other | 0.16% | -0.04% | EXIT | |
| 39 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.16% | -0.11% | +11.33% | |
| 40 | VZLA | Vizsla Silver CORP | Stock-Other | 0.16% | — | +30.29% | |
| 41 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.15% | +0.24% | — | |
| 42 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.15% | +0.01% | +16.87% | |
| 43 | SEA1EUR | Seabridge Gold Inc | Stock-Other | 0.14% | -0.15% | EXIT | |
| 44 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.13% | — | — | |
| 45 | VAL | Valaris Limited | Stock-Energy | 0.13% | — | -31.74% | |
| 46 | EMX | Emx Royalty CORP | Stock-Other | 0.12% | — | — | |
| 47 | SD | Sandridge Energy Inc | Stock-Other | 0.09% | -0.03% | +58.89% | |
| 48 | NE | Noble Corporation plc | Stock-Energy | 0.08% | -0.07% | EXIT | |
| 49 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.07% | +0.08% | — | |
| 50 | TDW | Tidewater Inc | Stock-Energy | 0.06% | +0.01% | — |
According to official SEC Form 13F filings, Privium Fund Management B.V. reported a total U.S. public equity portfolio value of $544.2M across 55 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPOT, TSLA, SHOP) accounted for 52.9% of total reported equity market value during Q2 2025.
During Q2 2025, Privium Fund Management B.V.'s top holdings by market value included SPOT (18.3%)、TSLA (16.1%)、SHOP (10.6%). The largest single position, SPOT, represented 18.3% of total portfolio value.
In Q2 2025, Privium Fund Management B.V. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.